chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt recvd 3 doses of Engerix-B & was found to have a neg titer; pt recvd 4th dose of Engerix-B 4MAR92 & now had a pos result;
Pain from neck down to wrist, which extends to forearm. Difficulty moving arm. Lost sleep due to pain in left arm.
Fever, chills, nausea, body ache, headache, disorientation unable to perform work duties
Rash in body/Rash in legs/Rash in stomach/Rash in back; Fever; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash in body/Rash in legs/Rash in stomach/Rash in back) and PYREXIA (Fever) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 11-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (Rash in body/Rash in legs/Rash in stomach/Rash in back) and PYREXIA (Fever). At the time of the report, RASH (Rash in body/Rash in legs/Rash in stomach/Rash in back) and PYREXIA (Fever) outcome was unknown.            concomitant medication was not reported treatment information was not provided    This case was linked to MOD-2021-132295 (Patient Link).
Patient is a 16-year-old boy with no significant past medical history presents to the emergency department with concerns for chest pain and shortness of breath.  Patient had his second dose of the Pfizer Covid vaccine 3 days ago.  Initially after the dose he did experience some myalgias, fatigue, and a sore throat.  The symptoms lasted overnight and into the following day.  They then remitted.  Yesterday, patient was feeling well in the morning, however, in the evening he began to experience significant shortness of breath.  This shortness of breath along with some anterior throat and upper chest discomfort with deep respirations.  He denied any associated nausea, vomiting, or sweating.  With these symptoms he went to hospital.  There he was evaluated and a chest x-ray was performed.  Patient's chest x-ray did not show any concerning findings.  Patient was discharged in stable condition with albuterol and encouraged to follow-up with his primary care physician.   Today, patient's shortness of breath and chest pain returned.  He states that it is in the center of her chest with occasional radiation to his jaw.  He denies any associated nausea, vomiting, or diaphoresis.  His pain was initially severe in route to the emergency department, however, it has lessened and is now 4 out of 10 in severity.  Patient otherwise denies any other fevers, lightheadedness, change in vision, abdominal pain, constipation, diarrhea, or dysuria.  Medical Decision Making: Pt presented for chest pain.  EKG was given to me shortly after obtaining it.  This showed ST elevation inferiorly and laterally with possible reciprocal change in I, aVL & V1.  Troponin was markedly elevated.  I discussed case with our interventional cardiologist initially who wanted to take pt to the cath lab.  However, pt is a minor and he noted that he couldn't cath a minor.  This decision was made after the patient was already in the cath lab.  Therefore, I contacted Hospital and discussed this case with the on call cardiologist.  He recommended pt be tranferred to the ED where they will evaluate him and possibly do an echo of his heart.  I discussed this with the ED physician at hospital who agreed to see pt.  He was then tranferred via ambulance for further care.
Patient in clinic with swelling to left deltoid area hot to touch. Oral temp normal. Mom states applied heat to area day of injection.
PT Presented approximately 20 mins after 2nd dose lightheaded. Pt had similar response after 1st dose. Pt history and vitals obtained. After approximately 5 mins PT stated she felt better. Pt monitored full 30 mins and released and advised to call 911 w/any further issues.
On October 27, 2002, patient experienced burning and itching sensation in toes and ball of right foot. October 28,2002 red dots appeared on bottom of right foot and toes began to swell. Patient saw physician and was diagnosed with angioedema. Treated with epinephirine and cortisone shots with relief of symptoms. On November 8, 2002, patient noted index finger on left had was red and itchy. On November 9, 2002, red dots, burning, itching and swelling of left hand were noted. Treated with oral prednisone. On November 10, 2002, red dots noted to increase and appear on palm of left hand. Treated with cortisone shots. Symptoms resolved. Follow up information received on 2/11/03 On Feb 11 2003 patient reports new findings of Deep vein thrombosis, rheumatoid arthritis, systemic lupus erythematos and probable hyperthyroidism.
Uncontrollable shivering began around 1:45 am. I had laid down about 30 minutes before but couldn't sleep so I got up. Shivers began as soon as I got out of bed. Lasted at least 1 hour (fell asleep at some point). I normally sleep with only a night shirt and a sheet. During this event I had 2 blankets, sweat pants, hooded sweatshirt, socks AND my cat got under the covers against my stomach! She never does that. But still had shivers. Woke with a headache but then was fine.
This spontaneous report as received from a registered nurse refers to a patient of unknown demographics. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant therapy were not reported. On 05-JUL-2018, the patient was vaccinated with improperly stored doses of PROQUAD either from lot # R002939, expiry date: 29-JUL-2019 or lot # R006218, expiry date: 28-AUG-2019 (dose, frequency and route were not reported) for prophylaxis. Sterile diluent (MRK) was properly stored. No adverse effects were reported. No product quality complaint was involved. The PROQUAD was stored in temperature of 15 degree Fahrenheit (F) to 46 F for 14 hours on 16-JUN-2018. No previous temperature excursion was reported. A digital data logger was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1808USA004381: Original Case: 1808USA001261; US-009507513-1808USA004380: Original Case: 1808USA001261; US-009507513-1808USA004379: Original Case: 1808USA001261; US-009507513-1808USA004376: Original Case: 1808USA001261; US-009507513-1808USA004377: Original Case: 1808USA001261; US-009507513-1808USA004378: Original Case: 1808USA001261; US-009507513-1808USA004382: Original Case: 1808USA001261; US-009507513-1808USA004383: Original Case: 1808USA001261; US-009507513-1808USA004384: Original Case: 1808USA001261; US-009507513-1808USA004385: Original Case: 1808USA001261; US-009507513-1808USA004386: Original Case: 1808USA001261; US-009507513-1808USA004362: Original Case: 1808USA001261; US-009507513-1808USA004387: Original Case: 1808USA001261; US-009507513-1808USA004388: Original Case: 1808USA001261; US-009507513-1808USA004363: Original Case: 1808USA001261; US-009507513-1808USA004364: Original Case: 1808USA001261; US-009507513-1808USA004389: Original Case: 1808USA001261; US-009507513-1808USA004390: Original Case: 1808USA001261; US-009507513-1808USA004391: Original Case: 1808USA001261; US-009507513-1808USA004365: Original Case: 1808USA001261; US-009507513-1808USA004392: Original Case: 1808USA001261; US-009507513-1808USA004393: Original Case: 1808USA001261; US-009507513-1808USA004394: Original Case: 1808USA001261; US-009507513-1808USA004395: Original Case: 1808USA001261; US-009507513-1808USA004396: Original Case: 1808USA001261; US-009507513-1808USA004366: Original Case: 1808USA001261; US-009507513-1808USA004367: Original Case: 1808USA001261; US-009507513-1808USA004368: Original Case: 1808USA001261; US-009507513-1808USA004397: Original Case: 1808USA001261; US-009507513-1808USA004398: Original Case: 1808USA001261; US-009507513-1808USA004399: Original Case: 1808USA001261; US-009507513-1808USA004400: Original Case: 1808USA001261; US-009507513-1808USA004369: Original Case: 1808USA001261; US-009507513-1808USA004370: Original Case: 1808USA001261; US-009507513-1808USA004401.
Inconsolable crying and screaming first night. Next few days listless, Head size swelled.  Increased from 80th percentile to 90th percentile.  Failed to reach milestones..  Left eye discharge.
KINRIX administered to a 7 month old. No symptoms of vaccine reaction reported by parent.
Patient had chills and low grade fever. Patient fell down after his legs gave way after getting out of bed.
w/in 24 hrs sore arm, erythema, rash extending from inject site to elbow; pt not feeling well for 2 to 3 days;
Within a half hour to 45 minutes post injection, I started having a sharp pain in my left eyebrow. over the next hour or so, the pain worsened around my left eye,  and I noticed a numbness in my forehead and upper cheeks (Similar feeling to botox but also slightly tingly). The discomfort lasted throughout the evening.  By bedtime, I was extremely fatigued and having feverish symptoms (chills, aches, headache, fatigue) though my body temp was not elevated much. When I woke up the next morning, my temperature was increasing, chills and body aches were worse. I was somewhat expecting that, given accounts from others. Highest temp was 102.8 over the next 24 hours. But most concerning was my resting heartrate was elevated all day (tracked via apple watch). My resting HR even while sleeping was from the upper 80s and as high as 103 bpm.  After bedtime that night, I started having pretty severe body aches in my torso. Most of the other aches had lessened but these got worse, preventing sleep, and lasted through most of sunday 5/30. By evening, I felt much better, and by Monday, I was back to normal, all symptoms gone.
Spuratic events of hives.  Small areas have occurred on back, stomach and lips swelling.   I have been able to control using otc medications benadryl.
Painful palpable lump at site of injection 3 days post vaccine, still present as of 3/29/18.
Patient was vaccinated on 5/1/21 and 5/22/21, so was fully vaccinated when testing positive for COVID-19 on 9/26/21.
No additional AE; PROQUAD vaccine was administered to a patient after a temperature excursion      ?; This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender.  There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.    On 09-AUG-2022, the patient was vaccinated with a dose of improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) 0.5 mL, lot # W006585, expiration date: 23-AUG-2023, albumin status has been verified as recombinant human albumin (rHA) (route of administration and anatomical location were not reported) for prophylaxis. Administered dose of vaccine experienced the temperature excursion of -13.2 degrees Celsius (C) for 4 hours (LLT: Product storage error temperature too low). There were no previous excursions reported. No adverse event was reported.
VR recipient with history of SVT/PVC's, anxiety and cardiac ablasion felt symptoms of lower chest pain and PVC's approx. 5 min after vaccination; a somewhat normal feeling for her. EMS was called
Pt woke up an his arm was very stiff, swollen; he could not lift his left arm.  Patient had lesions/spots on the left arm.  Progressively over the next six days, the spots spread over his legs, calves, feet, hands, and torso.
Coughing; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Coughing) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-May-2021, the patient experienced COUGH (Coughing). At the time of the report, COUGH (Coughing) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information provided by the reporter and no concomitant medication was reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Extreme swelling of Face. Eventually swelling went away on its own over the course of a few hours. Have pictures of reaction. Afraid of getting second dose.
Muscle pain, headache, nausea. Muscle pain instantly, headache 6 hrs later w nauseous
Headache & NauseaVomiting Narrative: 2/4 increased saliv at 2pm, nausea and tingling tongue, 2/4 at 9pm body aches and headache 2/5.
Tongue swelling, seen in ED and discharged.  Works in hospital ICU and will continue to monitor during shift.
This spontaneous case was reported by a consumer and describes the occurrence of SWELLING OF EYELID (Swelling around both eye lids) and PRURITUS (Itchiness along her upper back) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced SWELLING OF EYELID (Swelling around both eye lids) and PRURITUS (Itchiness along her upper back). At the time of the report, SWELLING OF EYELID (Swelling around both eye lids) and PRURITUS (Itchiness along her upper back) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-065273 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 31-Mar-2021: Additional information received updated outcome of the events.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-065273:Dose 2
Patient brought into clinic by mother for immunizations and patient needing PPD placed for school. Patient due for HPV, FLU, and MEN-B. Handouts given and reviewed with mother and patient. Mom agreeable to all vaccines but let patient decide about the HPV vaccine, mother had previously declined that vaccine for patient. Educated on HPV disease and vaccine, patient opted to receive HPV vaccine and mother supported that decision. Patient declined travel to high risk TB areas, signs/symptoms of TB, past exposure, or past positive PPD. Placed PPD on L. forearm. Patient tolerated well. Instructed patient and mother on PPD reading instructing to have it read by instructor or ER nurse in 48-72hours, as clinic will not be open on Saturday or Sunday. School requires 2-step manteaux, instructed patient to come back 1 week after first PPD is read to get 2nd PPD placed. Vaccine history form filled out for patient for school program.  Administered Flu shot and HPV vaccine in L. deltoid at 1146. After receiving HPV vaccine patient fainted with eyes rolling back and made a few involuntary jerky movements and body going limp. Cleared exam bed and mother of patient eased patient to lay down on exam bed, preventing patient from falling. Patient's gaze returned within seconds and patient tried to sit up. Mother and self coaxed patient to remain laying down and take slow deep breaths. Called supervisor for immediate assistance, getting snacks and juice for patient to drink, while I stayed with patient. Checked patient's vital signs temp 99.1F, Heart rate 82, BP (supine) 128/84, and respiratory rate 20, O2 saturation 100%. Supervisor opened window in exam room to let in some fresh cool air. Patient took a few sips of juice and a piece of chocolate. Patient reported feeling ok, but didn't know what happened. Self and supervisor reviewed with patient and mom that fainting after vaccines is common especially for teens, and patient hadn't eaten anything yet today. Observed patient for a few more minutes, and then had patient sit up. Checked vital signs again with patient sitting @ 1149 BP 124/81, 99.2F, HR 80, resp rate 18, O2 sats 99%. Patient took a few more sips of juice and declined anymore snacks. She stated she was feeling well. Self and supervisor still encouraged mom and patient to continue with vaccine series, reviewing external factors that can lead to fainting and still weighing the risk of the disease and vaccine reaction. Encouraging patient to eat prior to getting vaccines in the future.  Mother of patient opted not to give patient anymore shots at this visit. Instructed to patient and mother that patient did not receive the MEN B at this visit, so patient will still be due for that vaccine. Will consider receiving the vaccine in the future.  Patient feeling ok and ready to go home, instructed patient to stand up slowly, mother at patient's side for patient's assistance. Patient steady on her feet. Walked patient and mother out of office and encouraged to call with any questions/concerns.
Information has been received from a 83 year old female consumer with a penicillin allergy and a history of shingles "several years ago, and they reoccur every so often," who about two months ago on approximately 05-JAN-2008 was vaccinated with single dose of series of zoster vaccine live (Oka/Merck). Concomitant therapy included blood pressure medication and NEXIUM. Subsequently, after receiving zoster vaccine live (Oka/Merck) her shingles reoccurred and have gotten worse. The patient reported that the shingles reoccurred on her upper back, between her shoulder blades and on her bottom, and she stated her shingles are really itchy and they sting. In addition, she stated after receiving zoster vaccine live (Oka/Merck) she has been losing her hair and also some hair from her eyebrows. Unspecified medical attention was sought, there were no lab studies performed. At the time of the report the patient had not recovered. There was no product quality complaint involved. Follow up information from the registered nurse indicated she had no additional information to provide for this case because the patient had not yet contacted or returned to their office since the vaccine was administered. Follow-up information from the patient indicated "she still had shingles and her hair was still falling out." Follow-up information from the registered nurse indicated no further information is available. No additional information is available.
pt exp flu like sx; 6APR92 fever, unmeasured, diarrhea x 8, nausea, sore lt arm; no swelling or redness in arm; 7APR93 diarrhea subsided has intense headache which started this AM; fever subsided by early AM;
I have atopic dermatitis, and after receiving my booster shot, my symptoms became much worse.; I have atopic dermatitis, and after receiving my booster shot, my symptoms became much worse.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID: (005570). The reporter is the patient.  A male patient received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer), for COVID-19 immunization. The following information was reported: DERMATITIS ATOPIC (non-serious), CONDITION AGGRAVATED (non-serious), outcome "unknown" and all described as "I have atopic dermatitis, and after receiving my booster shot, my symptoms became much worse.".  Additional information: Patient stated, I have atopic dermatitis, and after receiving my booster shot, my symptoms became much worse. I've talked to one other person who experienced the same situation as myself and have found some information online that also suggests the vaccine can cause increased symptoms of atopic dermatitis.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Severe swelling of lymph nodes under left underarm with pain; Severe swelling of lymph nodes under left underarm with pain; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0196) via an unspecified route of administration in the left arm on an unknown date in Jun2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity, depression and hidradenitis suppurativa. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included losartan (MANUFACTURER UNKNOWN), montelukast sodium (MONTELUCAST) and escitalopram (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. The patient previously received clindamycin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW021) via an unspecified route of administration in the left arm on 05Jun2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 27Jun2021, the patient experienced severe swelling of lymph nodes under left underarm with pain. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe swelling of lymph nodes under left underarm with pain was not resolved at the time of this report.